A marker linked to inflammation, C-reactive protein, may increase significantly during the follicular phase of the menstrual cycle in female patients ...

The mass layoffs of federal workers under Health Secretary Robert F. Kennedy Jr. have impaired data-gathering on critical ...

Vertex Pharma's £1.65 million ($2.05 million) gene-editing therapy for sickle cell disease (SCD), Casgevy ... according to the health technology assessment (HTA) agency. It is estimated that ...

Pfizer is voluntarily withdrawing its sickle cell disease (SCD) therapy Oxbryta ... crises and fatal events which require further assessment," and the company has pulled the drug from the market ...

Transcription factor networks disproportionately enrich for heritability of blood cell phenotypesPublication: ...

Q4 2024 Earnings Call Transcript March 31, 2025 Operator: Ladies and gentlemen, thank you for standing by. Welcome to the ...

Discover Nkarta's groundbreaking cell therapy advancements, robust financials, and investment potential. Click here to read my most recent analysis of NKTX.

This finding supports the historical assessment of splenomegaly based on spleen length ... in our sample reported a history of sickle cell trait and none reported sickle cell disease or other ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...